Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma
What can be expected from the Dermatological Drugs Market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
Our 273-page report provides 208 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of the dermatological drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
See revenue forecasts for the leading submarkets and indications How will submarkets perform to 2026? Our study forecasts revenues in the following Dermatological Drugs submarkets: • Psoriasis • Skin Infections • Acne • Dermatitis
See detailed profiles or revenue forecasts for some the leading products in the market How will leading drugs perform to 2026? Our study provides detailed profiles or forecasts revenues for a number of drugs in the dermatological drugs market including: • Humira • Stelara • Enbrel • Remicade • Taltz • Otezla • Cosentyx • Cubicin • Zyvox • Valtrex • Canesten • Lamisil • Bactroban • Solodyn • Epiduo • Claravis • Aczone • Differin • Abscorical/Epirus • Ziana • Doryx • Bepanthen/Bepanthol • Protopic • Dermovate • Elocon
See revenue forecasts for the leading international markets How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including: • US • EU5 – Germany, UK, France, Italy and Spain • China • Japan • India • Russia • Brazil
Leading companies and potential for market growth Visiongain forecasts overall revenue for the Dermatological Drugs Market will reach $39.26bn in 2026. We predict a high revenue growth over the forecast period driven by an aging population, increasing patient expectations and a higher incidence of skin conditions, rapid growth of emerging economies and emerging dermatological drug technologies.
Our work analyses the key companies in the market. See Visiongain’s analysis of six leading companies, including these: • Galderma (Nestle Skin Health) • Johnson & Johnson • AbbVie • GlaxosmithKline • Pfizer • LEO Pharma
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook • Historic revenue, analysis and discussion of company performance • Analysis of major products currently on the market • Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the dermatological drugs industry? Our new report discusses issues and events affecting the dermatological drugs market. You will find discussions, including qualitative analyses: • Highly fragmented and competitive market with significant variations in different geographic regions • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities • Future paradigm-shifting pipeline products • Patent expirations and invalidations of major drugs • Launches of new drug categories • Biosimilar approvals
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma In summary, our 273-page report gives you the following knowledge: • Revenue forecasts to 2026 for the Dermatological Drugs market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2026 for each major submarket – discover prospects for leading dermatological drugs in the following areas: psoriasis, skin infections, acne and dermatitis. • Detailed profiles or revenue forecasts to 2026 for 25 of the leading products in the dermatological drugs market – discover prospects for leading dermatological drugs: Humira, Stelara, Enbrel, Remicade Taltz, Otezla, Cosentyx, Cubicin, Zyvox, Valtrex, Canesten, Lamisil, Bactroban, Solodyn, Epiduo, Claravis, Aczone, Differin, Abscorical/Epirus, Ziana, Doryx, Bepanthen/Bepanthol, Protopic, Dermovate and Elocon. • Revenue forecasts to 2026 for eleven leading national market and one leading regional markets – US, EU5, China, Japan, India, Russia, and Braz. • Assessment of six leading companies – analysis of products, revenue, mergers & acquisitions, product type and product pipelines • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the over the counter medicine market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Dermatological Drugs: Market Overview 1.2 Global Dermatological Drugs Market Segmentation 1.3 Overview of Findings 1.4 Structure of the Report 1.5 Why You Should Read This Report 1.6 How This Report Delivers 1.7 Key Questions Answered by This Analytical Report 1.8 Who is This Report For? 1.9 Methodology 1.10 Frequently Asked Questions (FAQ) 1.11 Associated Visiongain Reports 1.12 About Visiongain
2. An Introduction to Dermatological Drugs 2.1 The Pharmaceutical Industry: A Brief Introduction 2.2 An Introduction to Dermatology 2.2.1 The Structure of Skin, Hair, and Nails 2.2.2 Hair and Nails 2.2.3 Sweat and Sebaceous Glands 2.2.4 Functions of the Skin 2.3 Common Skin Diseases 2.3.1 Acne: The Most Common Skin Disease 2.3.1.1 Acne: Epidemiology 2.3.1.2 Acne: Causes and Pathogenesis 2.3.1.3 Acne: Treatment 2.3.2 Dermatitis: Inflammation of the Skin 2.3.2.1 Atopic Dermatitis 2.3.2.2 Contact Dermatitis 2.3.2.3 Seborrhoeic Dermatitis 2.3.2.4 Nummular Dermatitis 2.3.2.5 Perioral Dermatitis 2.3.3 Psoriasis: A Complex Multi-factorial Disease 2.3.4 Rosacea: Vascular Instability 2.3.5 Alopecia: Excessive Shedding Of Hair 2.4 Skin Infections: A Serious Healthcare Threat 2.4.1 Bacterial Skin Infections 2.4.2 Fungal Skin Infections 2.4.3 Viral Skin Infections 2.5 Common Skin Treatments 2.5.1 Creams and Semisolid Emulsions 2.5.2 Ointments 2.5.3 Lotions 2.5.4 Solutions 2.5.5 Occlusive Therapy 2.5.6 Cleansing Agents 2.5.7 Powders and Hydrophilic Polymer 2.5.8 Anti-Infective Agents 2.5.9 Anti-Inflammatory Agents 2.6 Phases of Clinical Trials 2.7 Dermatological Drugs: Market Definition in this Report
3. The Global Dermatological Drugs Market, 2016-2026 3.1 The Global Dermatological Drugs Market: Market Overview 3.2 Categorisation of the Global Dermatological Drugs Market 3.3 The Global Dermatological Drugs Market in 2015 3.4 The Global Dermatological Drugs Market: Market Forecast 2016-2026 3.5 Dermatological Drugs: Changing Market Shares by Sector 2016-2026
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2016-2026 4.1 Psoriasis Treatments: The Dominance of Biologics 4.1.1 Leading Products in the Psoriasis Drugs Market, 2015 4.2 Psoriasis: Market Trends and Developments, 2016 4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview 4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing 4.2.3 The Disadvantages of Biologics in Psoriasis Treatment 4.3 Psoriasis Drugs: Market Forecast 2016-2026 4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2015-2026 4.4 Leading Drugs Used in the Treatment of Psoriasis 4.4.1 Humira (adalimumab) - AbbVie 4.4.1.1 Humira: Historical Sales Analysis, 2010-2015 4.4.1.2 Humira: Sales Forecast 2016-2026 4.4.1.3 Future Prospects for Biosimilar Versions of Humira 4.4.2 Stelara (ustekinumab) – Johnson & Johnson 4.4.2.1 Stelara: Historical Sales Analysis, 2010-2014 4.4.2.2 Stelara: Sales Forecast 2016-2026 4.4.2.3 Intensifying Competition for Stelara 4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda 4.4.3.1 Enbrel: Co-Promotions and Marketing Rights 4.4.3.2 Enbrel: Historical Sales Analysis, 2008-2015 4.4.3.2 Enbrel: Patent Expiries and Potential Competition, 2016-2026 4.4.3.4 Enbrel: Sales Forecast 2016-2026 4.4.3.5 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years 4.4.3.6 Competition from Other Drugs 4.4.3.7 Biosimilar Competition for Enbrel 4.4.4 Remicade (infliximab) – Johnson & Johnson 4.4.4.1 Remicade: Historical Sales Analysis, 2010-2015 4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2016-2026 4.4.4.3 Remicade: Sales Forecast 2016-2026 4.4.5 Taltz (ixekizumab) – Eli Lily 4.4.5.1 Taltz: Sales Forecast 2016-2026 4.4.6 Otezla (apremilast) – Celgene 4.4.6.1 Otezla: Sales Forecast 2016-2026 4.4.7 Cosentyx (secukinumab) - Novartis 4.4.7.1 Cosentyx: Sales Forecast 2016-2026 4.4.8 Other Psoriasis Drugs 4.4.8.1 Cimzia (certolizumab) - UCB 4.4.8.2 Sorilux (calcipotriene foam) - GSK 4.4.8.3 Other Psoriasis Drugs: Sales Forecast 2016-2026 4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2016-2026 5.1 Skin Infection Drugs: Abundant Growth Opportunities 5.1.1 Leading Products in the Skin Infection Drugs Market, 2015 5.2 Skin Infection Drugs: Market Forecast 2016-2026 5.2.1 Skin Infection Drugs: Changing Market Shares by Leading Drugs 2016-2026 5.3 Leading Drugs Used in the Treatment of Skin Infections 5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co 5.3.2 Acquisition By Merck & Co 5.3.3 Generic Competition For Cubicin 5.3.4 Cubicin: Sales Forecast 2016-2026 5.3.5 Lifecycle Management Strategies for Cubicin 5.4 Zyvox (linezolid) - Pfizer 5.4.1 Zyvox: Historical Sales Analysis, 2010-2014 5.4.2 Zyvox: Sales Forecast 2016-2026 5.4.3 The Threats to Zyvox Sales from Competing New Drugs 5.5 Canesten (clotrimazole) - Bayer 5.5.1 Canesten: Historical Sales Analysis, 2011-2014 5.5.2 Canesten: Sales Forecast 2016-2026 5.6 Valtrex (valaciclovir) - GSK 5.6.1 Valtrex: Historical Sales Analysis, 2010-2014 5.6.2 Valtrex: Sales Forecast 2016-2026 5.7 Bactroban (mupirocin) - GSK 5.7.1 Bactroban: Historical Sales Analysis, 2010-2013 5.7.2 Bactroban: Sales Forecast 2015-2026 5.8 Lamisil (terbinafine) - Novartis 5.8.1 Lamisil Patent Expiry 5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems 5.8.3 Lamisil: Sales Forecast 2016-2026 5.9 Other Skin Infection Drugs 5.9.1 Dalvance (dalbavancin) - Durata Therapeutics 5.9.2 Jublia (efinaconazole) - Valeant 5.9.3 Kerydin (tavaborole) - Anacor 5.9.4 Sivextro (tedizolid) – Cubist Pharmaceuticals 5.9.5 Zovirax (acyclovir) - Valeant/GSK 5.9.5.1 Valeant Acquires Zovirax In US And Canada 5.9.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic 5.9.6 Other Skin Infection Drugs: Sales Forecast 2016-2025 5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2016-2026 6.1 Acne Drugs: A Diversified Market 6.1.1 Leading Products in the Acne Drugs Market, 2015 6.2 Acne Drugs Market: Recent Trends and Developments 6.2.1 The Rise of Combination Therapies in Acne Treatment 6.2.2 Oral Contraceptives in Treating Acne 6.2.3 The Threat of Generic Competition in the Acne Drugs Market 6.3 Acne Drugs: Market Forecast 2015-2026 6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2015-2026 6.4 Leading Drugs in the Acne Drugs Market 6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health 6.4.1.1 Epiduo: Sales Forecast 2016-2026 6.4.1.2 Galderma Settlement Agreement over Generic Epiduo 6.4.1.3 Paediatric Approval for Epiduo 6.4.2 Solodyn (minocycline) - Valeant 6.4.2.1 Solodyn: Sales Forecast 2016-2026 6.4.2.2 Antitrust Action Over Solodyn Pay-For-Delay Deals 6.4.2.3 Impax And Medicis Collaborating On Advanced Solodyn 6.4.2.4 Medicis And Lupin Settle 6.4.3 Claravis (isotretinoin) - Teva 6.4.3.1 Claravis: Sales Forecast 2016-2026 6.4.4 Aczone (dapsone) - Allergan 6.4.4.1 Aczone: Sales Forecast 2016-2026 6.4.5 Differin (adapalene) – Galderma/ Nestlé Skin Health 6.4.5.1 Recent Generic Competition to Differin 6.4.5.2 Differin: Sales Forecast 2016-2026 6.4.5.3 Adapalene Gel to be Available OTC in the US 6.4.5.4 Federal Circuit Court Invalidates Differin Patents 6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma 6.4.6.1 Absorica/Epuris: Sales Forecast 2016-2025 6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International 6.4.7.1 Valeant’s Patent Settlement with Actavis Over Ziana 6.4.7.2 Ziana: Sales Forecast 2016-2026 6.4.8 Doryx (doxycycline) – Actavis/ Mayne Pharma 6.4.8.1 Lifecycle Management Strategies for Doryx 6.4.8.2 Divestment Agreement with Mayne Pharma 6.4.8.3 Generic Competition for Doryx 6.4.8.4 Doryx: Sales Forecast 2016-2026 6.4.9 Other Acne Drugs 6.4.9.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant 6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya ANDA 6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, And Watson 6.4.9.2 Amnesteem (isotretinoin) - Mylan 6.4.9.2.1 Amnesteem: Financial Analysis 6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer 6.4.9.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline 6.4.9.5 Veltin (tretinoin/clindamycin) - GSK 6.4.9.6 Other Acne Drugs: Sales Forecast 2016-2026 6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2016-2026 7.1 Dermatitis Drugs: High Generic Penetration 7.1.1 Leading Products in the Dermatitis Drugs Market, 2015 7.2 Dermatitis Drugs: Market Forecast 2016-2026 7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2016-2026 7.3 Leading Drugs in the Dermatitis Drugs Market 7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer 7.3.1.1 Bepanthen: Sales Forecast 2016-2026 7.3.2 Elocon (mometasone) - Merck & Co 7.3.2.1 Elocon: Sales Forecast 2016-2026 7.3.3 Protopic (tacrolimus) – LEO Pharma 7.3.3.1 Protopic Benefits from Expanded Indication 7.3.3.2 Generic Competition For Protopic 7.3.3.3 Protopic: Sales Forecast 2016-2026 7.3.4 Dermovate -GSK 7.3.4.1 Dermovate: Sales Forecast 2016-2026 7.3.5 Other Dermatitis Drugs: Sales Forecast 2016-2026 7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets for Dermatological Drugs, 2016-2026 8.1 The Dermatological Drugs Market by Region 8.1.1 The Global Distribution of Dermatological Drugs in 2015 8.2 Leading National Markets: Forecast 2016-2026 8.2.1 Changing Market Shares by Region, 2015-2026 8.3 Regional Dermatological Drugs Markets: Analysis and Forecasts, 2015-2026 8.3.1 United States: The Largest Dermatological Drugs Market 8.3.1.1 The Impact of an Expanding Medicare Coverage 8.3.1.2 Legislative Environment Stimulating Biosimilars Market? 8.3.1.3 US Dermatological Drugs Market: Market Forecast 2016-2026 8.3.2 The EU5 Markets: Growth Expected in Each Country 8.3.2.1 EU5 Dermatological Drugs Market: Market Forecast 2016-2026 8.3.2.1.1 EU5 Markets: Changing Market Shares by Country, 2015-2026 8.3.2.2 Germany 8.3.2.2.1 German Dermatological Drugs Market: Market Forecast 2016-2026 8.3.2.3 France 8.3.2.3.1 French Dermatological Drugs Market Forecast 2016-2026 8.3.2.4 UK 8.3.2.4.1 UK Dermatological Drugs Market Forecast 2016-2026 8.3.2.5 Italy 8.3.2.5.1 Italian Dermatological Drugs Market Forecast 2016-2026 8.3.2.6 Spain 8.3.2.6.1 Spanish Dermatological Drugs Market Forecast 2016-2026 8.3.3 Japan 8.3.3.1 The Cost of Treatment in Japan 8.3.3.2 Japanese Pharmaceutical Industry Regulatory Reform 8.3.3.3 Japanese Dermatological Drugs Market Forecast 2016-2026 8.3.4 China 8.3.4.1 Expansion of Healthcare Coverage and Reimbursement in China 8.3.4.2 Improving Public Perception of Dermatology in China 8.4.3.3 Price Controls and the Anhui Model 8.3.4.4 Chinese Dermatological Drugs Market Forecast 2016-2026 8.3.5 India 8.3.5.1 The Effects of the Drug Prices Control Order of 2013 8.3.5.2 India’s Expansion of Healthcare Provision 8.3.5.3 Indian Dermatological Drugs Market Forecast 2016-2026 8.3.6 Brazil 8.3.6.1 The Growth in Brazil’s Healthcare Landscape 8.3.6.2 Clearer Access to Medicines in Brazil 8.3.6.3 Brazilian Dermatological Drugs Market Forecast 2016-2026 8.3.7 Russia 8.3.7.1 Pharma2020 Strategy - Healthcare and Industry Reform 8.3.7.2 Russian Dermatological Drugs Market Forecast 2016-2026 8.3.8 Rest of the World 8.3.8.1 The Rest of the World Dermatological Drugs Market Forecast 2016-2026
9. Leading Companies in the Dermatological Drugs Market, 2016-2026 9.1 Dermatological Drugs – A Rapidly Consolidating Market 9.2 Galderma (Nestle Skin Health S.A.) 9.2.1 Galderma: Dermatological Drugs Portfolio, 2016 9.2.2 Galderma: Recent Developments 9.2.2.1 Nestlé’s Acquisition of Galderma 9.2.2.2 Approval and Launch of Soolantra for Rosacea 9.3 Johnson & Johnson 9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015 9.3.2 Johnson & Johnson: Dermatological Drug Development Pipeline, 2016 9.4 AbbVie 9.4.1 AbbVie: Dermatological Drugs Portfolio, 2016 9.5 GlaxoSmithKline (GSK) 9.5.1 GSK: Dermatological Drugs Portfolio, 2016 9.5.3 GlaxoSmithKline (GSK): Recent Developments 9.5.3.1 Business Restructuring Arrangements With Novartis 9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2016 9.6 Pfizer 9.6.1 Pfizer: Dermatological Drugs Portfolio, 2016 9.6.2 Pfizer: Dermatological Drugs Development Pipeline, 2016 9.7 LEO Pharma 9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2016 9.7.2 LEO Pharma: Dermatological Drugs Development Pipeline, 2016
10. Dermatological Drugs: Research and Development Pipeline, 2016-2026 10.1 Innovative Products Currently in Development Will Drive Growth 10.1.1 New Technology in R&D Pipeline Activities 10.1.1.1 Reformulation 10.1.1.2 Combination Treatments 10.1.1.3 New Mechanisms and Drug Delivery Technologies 10.1.1.4 Potential Market Entrants 10.2 Psoriasis Drugs Development Pipeline, 2016 10.2.1 Psoriasis Drugs in Phase 3 Development or Regulatory Approval Stage 10.2.1.1 AMG 827 (brodalumab) - AstraZeneca/ LEO Pharma 10.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma 10.2.1.3 CNTO 1959 (guselkumab) - MorphoSys/ Janssen 10.2.1.4 LAS41008 (dimethyl fumarate) - Almirall 10.2.1.5 MK-3222/SCH 900222 (tildrakizumab) – Merck/Sun Pharma 10.2.2 Psoriasis Drugs in Phase 2 Development 10.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly 10.2.2.2 PH-10 (Rose Bengal) - Provectus Biopharmaceuticals 10.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical Development 10.3 Skin Infection Drugs Development Pipeline, 2016 10.3.1 Drugs in Phase 3 Development for Skin Infections 10.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals 10.3.1.2 NB-001 - NanoBio Corporation 10.3.1.3 Luliconazole - Topica Pharmaceuticals 10.3.2 Drugs in Phase 2 Development for Skin Infections 10.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections 10.4 Acne Drugs Development Pipeline, 2016 10.4.1 Drugs in Phase 3 Development for Acne 10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) - GlaxoSmithKline 10.4.1.2 Visonac (photodynamic therapy) - Photocure 10.4.2 Drugs in Phase 2 Development for Acne 10.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne 10.4.4 A Possible Vaccine for Acne 10.5 Dermatitis Drugs Development Pipeline, 2016 10.5.1 Drugs in Phase 3 Development for Dermatitis 10.5.1.1 Toctino (alitretinoin) - GSK 10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals 10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) - Pierre Fabre 10.5.1.4 REGN668/SAR231893 (dupilumab) - Regeneron/ Sanofi 10.5.2 Drugs in Phase 2 Development for Dermatitis 10.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis 10.6 Other Dermatological Drugs Development Pipeline, 2016 10.6.1 Other Dermatological Drugs: Filed or Recently Launched 10.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall 10.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera 10.6.1.3 Mirvaso (brimonidine) - Galderma 10.6.1.4 Picato (ingenol mebutate) - LEO Pharma 10.6.1.5 Xolair (omalizumab) - Novartis/ Roche 10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2016 10.6.2.1 CD5024 (ivermectin) - Galderma 10.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E Herbal Biotechnology 10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2016
11. Qualitative Analysis of the Dermatological Drugs Market, 2016-2026 11.1 Market Factors Influencing Dermatological Drugs 11.2 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026 11.2.1 Strengths 11.2.1.1 The High Unmet Clinical Need in Dermatology 11.2.1.2 A Healthy Pipeline of Development-Stage Products 11.2.1.3 Strong Industry-Physician Relationships 11.2.2 Weaknesses 11.2.2.1 Limited Efficacy and Adverse Effects May Impact Product Uptake 11.2.2.2 Patient Adherence – A Major Challenge to Treatment Design 11.2.2.3 Impending Patent Expiries and the Challenges Posed by Generic Competition 11.2.3 Opportunities 11.2.3.1 The High-Growth Sectors in Dermatology 11.2.3.2 Personalised Dermatology: Technological Advances in Genomics 11.2.3.3 Advances in Topical Drug Delivery Methods Offers Product Differentiation 11.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth? 11.2.4 Threats 11.2.4.1 Uncertain Surrounding Reimbursement and Payment Approvals 11.2.4.2 The Rising Cost of Research and Development 11.2.4.3 Downward Pressures on Drug Prices 11.3 Porter’s Five Force Analysis of the Global Dermatological Drugs Market, 2016-2026 11.3.1 Threat of New Entrants 11.3.2 Threat of Substitutes 11.3.3 Rivalry among Competitors 11.3.4 Power of Buyers 11.3.5 Power of Suppliers
12. Conclusions 12.1 Overview of Current Market Conditions and Market Forecast, 2015-2026 12.2 Leading Sectors in Dermatological Drugs in 2015 12.3 Leading Regions in the Dermatological Drugs Market in 2015 12.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2016-2026 12.5 What Does The Future Hold For Dermatological Drugs?
13. Glossary
Associated Visiongain Reports Appendix A Appendix B Visiongain’s Bespoke Research Service Some Associated Reports Visiongain Report Sales Order Form About Visiongain Report Evaluation Form
List of Tables Table 2.1 Clinical Trial Phases, 2016 Table 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn) and Market Shares (%), 2015 Table 3.2 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2015-2020, 2020-2026, 2015-2026 Table 3.4 The Global Dermatological Drugs Market by Sector: Market Share (%), 2015, 2020 and 2026 Table 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($bn) and Market Shares (%), 2015 Table 4.2 Psoriasis Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2015, 2020 and 2026 Table 4.4 Humira Historical Sales: Revenue ($bn) and AGR (%), 2010-2015 Table 4.5 Humira AbbVie Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.6 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015 Table 4.7 Stelara Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.8 Enbrel Historical Sales by Company: Revenue ($bn) and AGR (%), 2008-2015 Table 4.9 Enbrel Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.10 Remicade Historical Sales: Revenue ($bn), 2010-2015 Table 4.11 Remicade Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.12 Taltz: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2026 Table 4.13 Otezla Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.13 Cosentyx Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.14 Other Psoriasis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn) and Market Share (%), 2015 Table 5.2 Skin Infection Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2015, 2020 and 2026 Table 5.4 Cubicin Sales Forecast: Revenue($bn), AGR(%) and CAGR(%), 2015-2026 Table 5.5 Zyvox: Historical Sales: Revenue ($bn) and AGR(%), 2010-2014 Table 5.6 Zyvox: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.7 Canesten: Historical Sales: Revenue ($bn), and AGR (%), 2011-2014 Table 5.8 Canesten: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.9 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014 Table 5.10 Valtrex: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.11 Bactroban: Historical Sales: Revenue ($bn) and AGR (%), 2010-2013 Table 5.12 Bactroban Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.13 Lamisil Novartis Sales Forecast: Revenue ($bn), AGR (%), and CAGR (%), 2015-2026 Table 5.14 Other Skin Infection Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.1 Top Drugs In The Acne Drugs Market: Revenue ($bn) and Market Share (%), 2015 Table 6.2 Acne Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2015, 2020 and 2026 Table 6.4 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.5 Solodyn (Valeant) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.6 Claravis (Teva) Sales Forecast: Revenue ($bn), AGR%, and CAGR (%), 2015-2026 Table 6.7 Aczone (Allergan) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.8 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR%), 2015-2026 Table 6.9 Absorica/Epuris Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.10 Ziana Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.11 Doryx Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.12 Other Acne Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 7.1 Top Drugs In The Dermatitis Drugs Market: Revenue ($bn) and Market Share (%), 2015 Table 7.2 Dermatitis Drugs Market: Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2015, 2020, 2026 Table 7.4 Bepanthen/Bepanthol Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 7.5 Elocon Sales Forecast: Revenue ($bn), AGR (%) CAGR (%), 2015-2026 Table 7.6 Protopic Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 7.7 Dermovate Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 7.8 Other Dermatitis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn) and Market Share (%), 2015 Table 8.2 Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2015-2026 Table 8.3 The Global Dermatological Drugs Market Forecast by Region: CAGR (%), 2015-2020, 2020-2026, and 2015-2026 Table 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2015, 2020 and 2026 Table 8.5 The US Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.6 US Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.7 The EU5 Dermatological Drugs Market by Country Revenue ($bn) and Market Share (%), 2015 Table 8.8 The EU5 Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2015, 2020 and 2026 Table 8.10 The German Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.13 The French Dermatological Drugs Market Forecast: Revenue($bn, AGR (%)and CAGR (%), 2015-2026 Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.15 The UK Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.17 The Italian Dermatological Drugs Market Forecast: ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.19 The Spanish Dermatological Drugs Market Forecast: Revenue($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.21 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.23 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%) and CAGR (%), 2015-2026 Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.25 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.27 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026 Table 8.29 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 8.30 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), Market Share (%) and CAGR (%), 2015-2026 Table 8.31 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 9.1 Galderma: Company Overview, 2016 Table 9.2 Johnson & Johnson: Company Overview, 2016 Table 9.3 AbbVie: Company Overview, 2016 Table 9.4 GlaxoSmithKline: Company Overview, 2016 Table 9.5 GlaxoSmithKline: Dermatological Drugs Pipeline, 2016 Table 9.6 Pfizer: Company Overview, 2016 Table 9.7 LEO Pharma: Company Overview, 2016 Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2016 Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2016 Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2016 Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2016 Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2016 Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2016 Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015 Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2016 Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2016 Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2016 Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2016 Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2016 Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2015-2025 Table 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2015, 2020 and 2026 Table 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn) and Market Shares (%), 2015 Table 12.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2015, 2020 and 2026 Table 12.4 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2015, 2020, 2026
List of Figures Figure 1.1 Global Dermatological Drugs Market: Market Sectors, 2016 Figure 2.1 Anatomy of Human Skin Figure 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn), 2015 Figure 3.2 The Global Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%) 2015-2026 Figure 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2015-2020 Figure 3.4 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2020-2026 Figure 3.5 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2015-2026 Figure 3.6 The Global Dermatological Drugs Market by Sector: Market Share (%), 2015 Figure 3.7 The Global Dermatological Drugs Market by Sector: Market Share (%), 2020 Figure 3.8 The Global Dermatological Drugs Market by Sector: Market Share (%), 2026 Figure 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($bn), 2015 Figure 4.2 Psoriasis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2015 Figure 4.4 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%) by Leading Drugs, 2020 Figure 4.5 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2026 Figure 4.6 Humira Historical Sales: Revenue ($bn) AGR (%), 2010-2015 Figure 4.7 Humira AbbVie Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.8 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015 Figure 4.9 Stelara Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.10 Enbrel Historical Sales by Company: Revenue ($bn), 2008-2015 Figure 4.11 Enbrel Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.12 Remicade Historical Sales: Revenue ($bn) and AGR (%), 2010-2015 Figure 4.13 Remicade Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.14 Taltz Sales Forecast: Revenue ($bn) and AGR (%), 2016-2026 Figure 4.15 Otezla Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.16 Cosentyx Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.17 Other Psoriasis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn), 2015 Figure 5.2 Skin Infection Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2015 Figure 5.4 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2020 Figure 5.5 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2026 Figure 5.6 Cubicin Sales Forecast: Revenue ($bn) AGR (%), 2015-2026 Figure 5.7 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014 Figure 5.8 Zyvox: Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.9 Canesten: Historical Sales: Revenue ($bn) and AGR (%), 2011-2014 Figure 5.10 Canesten: Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.11 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014 Figure 5.12 Valtrex Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.13 Bactroban: Historical Sales: Revenue ($bn) AGR (%), 2010-2013 Figure 5.14 Bactroban Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.15 Lamisil Novartis Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.16 Other Skin Infection Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-20265 Figure 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn), 2015 Figure 6.2 Acne Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2015 Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2020 Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2026 Figure 6.6 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.7 Solodyn (Valeant) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.8 Claravis (Teva) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.9 Aczone (Allergan) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.10 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.11 Absorica/Epuris Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.12 Ziana Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.13 Doryx Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.14 Other Acne Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 7.1 Top Drugs In The Dermatitis Drugs Market: Revenue ($bn), 2015 Figure 7.2 Dermatitis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2015 Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2020 Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2026 Figure 7.6 Bepanthen/Bepanthol Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 7.7 Elocon Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 7.8 Protopic Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 7.9 Dermovate Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 7.10 Other Dermatitis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn), 2015 Figure 8.2 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2015 Figure 8.3 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2020 Figure 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2026 Figure 8.5 US Dermatological Drugs Market Forecast: Revenue ($bn) AGR (%), 2015-2026 Figure 8.6 The EU5 Dermatological Drugs Market by Country: Revenue ($bn), 2015 Figure 8.7 Germany, France, UK, Italy, and Spain Dermatological Drugs Market Forecast: Revenue ($bn), 2015-2026 Figure 8.8 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2015 Figure 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2020 Figure 8.10 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2026 Figure 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.13 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025 Figure 8.14 The Italian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.15 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.16 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.17 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.18 The Indian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.19 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.20 The Russian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 8.21 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 11.1 Porter’s Five Force Analysis of the Dermatological Drugs Market, 2016 Figure 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), 2015, 2018, 2020, 2026 Figure 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn), 2015 Figure 12.3 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2015, 2020, 2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
